Please find enclosed herewith the Outcome of the Board Meeting dated 15/01/2026 for your reference.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech's board, meeting on 15 January 2026, approved the unaudited financial results for the quarter and nine months ended 31 December 2025. Revenue from operations for Q3 FY26 stood at just Rs 5 lakh, sharply down from Rs 22 lakh in Q3 FY25, while nine-month revenue fell to Rs 23 lakh from Rs 58 lakh a year earlier. Profit after tax for the quarter was Rs 1.05 lakh versus Rs 15.5 lakh in Q3 FY25, and for the nine months PAT was Rs 3.85 lakh versus Rs 43 lakh in the prior period, reflecting a steep earnings decline. Earnings per share for the nine months dropped to Rs 0.13 from Rs 1.41 previously. Statutory auditor Andros & Co. issued a clean limited review report with no qualifications.
The sharp drop in both revenue and profit compared to the year-ago period is a red flag for shareholders, suggesting weakening business activity. The departure of a director due to non-completion of KYC is a routine compliance matter and unlikely to move the stock, but the weak operating numbers are the main concern.